Last updated: February 24, 2026
What is the drug associated with NDC 62135-0773?
NDC 62135-0773 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody targeting B-cell maturation antigen (BCMA) used in the treatment of multiple myeloma.
Market Overview
Indications and approved uses
Blenrep is approved by the FDA for relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Competitive landscape
- Key competitors:
- Abecma (idecabtagene vicleucel). CAR T-cell therapy, approved for similar patient populations.
- Revlimid (elrefnatamab). Bispecific antibody in development.
- Farydak (panobinostat) and Pomalyst (pomalidomide). Other treatment options.
Market size estimations
- In 2022, the global multiple myeloma market was valued at approximately USD 15 billion.
- The relapsed/refractory segment accounts for roughly 50% of this market, estimated around USD 7.5 billion.
- Approximately 35,000 new cases annually in the U.S. with advanced disease requiring third-line or later treatments.
Adoption factors
- Efficacy demonstrated in multiple clinical trials.
- Mode of administration (intravenous).
- Safety profile, especially ocular toxicity, influences usage patterns.
Price structure analysis
Current pricing (as of 2023)
- List price for Blenrep is approximately USD 4,150 per 30-mg vial.
- Dosing is weight-based, often involving multiple vials per treatment cycle.
- Typical treatment span involves 3-4 cycles, resulting in total costs around USD 20,000 to USD 40,000 per patient.
Reimbursement landscape
- Coverage varies by payer; some integrate the drug into bundled chemotherapy payments.
- Special handling procedures required due to ocular toxicity risks, impacting administration costs.
Price comparisons
| Metric |
Blenrep |
Abecma |
Revlimid |
| List price per treatment |
USD 4,150 per vial |
USD 375,000 per CAR T dose |
Pricing not yet established |
| Treatment duration |
3-4 cycles |
Single infusion (patient-specific) |
In development |
| Major cost drivers |
Vial cost, administration cost |
Cell manufacturing, hospitalization |
Clinical trial and manufacturing |
Future price projections
Market trends
- Biosimilar and alternative therapies could pressure pricing.
- Demand may increase as clinical data expands, influencing potential price reductions.
- Payer negotiations are expected to impact net prices.
Forecast assumptions
- 2024-2028 CAGR of 3-5% in the commercial price due to inflation and market expansion.
- Volume growth driven by increased approval and correct treatment pathways.
Price outlook
- Near-term: Stable list pricing, pending market entry of competitors.
- Mid-term: Possible modest discounts as market matures.
- Long-term: Potential for price decreases of 10-15% influenced by biosimilar competition and expanded indications.
Conclusion
Blenrep's market relies heavily on its niche in the relapsed/refractory multiple myeloma space. Its pricing reflects manufacturing complexity, targeted therapy status, and competitive pressures. Future pricing hinges on market expansion, trial outcomes, and payer negotiations.
Key Takeaways
- The current list price for Blenrep is approximately USD 4,150 per vial.
- The total treatment cost per patient generally ranges between USD 20,000 and USD 40,000.
- Market growth is moderate, driven by increased indication approvals and potential biosimilar entry.
- Price reductions are expected over the next 3-5 years due to competitive dynamics.
- Reimbursement complexity primarily stems from toxicity management and administration costs.
FAQs
1. How does Blenrep pricing compare to other multiple myeloma therapies?
Blenrep's list price per vial is lower than CAR T-cell therapies like Abecma, but total treatment costs can be similar or higher, depending on dosing and duration.
2. What factors could influence Blenrep's future market penetration?
Efficacy data, safety profile, competitor product launches, and reimbursement policies will influence uptake.
3. Are biosimilars expected to impact Blenrep's price?
Biosimilars are less likely due to the complexity of monoclonal antibody manufacturing but may pressure prices of similar therapies.
4. How significant are administration costs for Blenrep?
Administration involves specialized handling due to ocular toxicity, increasing overall treatment expenses.
5. What is the outlook for the product’s price over the next five years?
Prices are expected to stabilize initially, with gradual decreases of 10-15% as market competition increases and biosimilar options emerge.
References
- U.S. Food and Drug Administration. (2020). Blenrep (belantamab mafodotin-blmf) prescribing information.
- IQVIA Institute. (2022). The Global Oncology Market.
- Medicare & Medicaid Services. (2023). Reimbursement policies for specialty drugs.
- Pharmaceutical Commerce. (2023). Monoclonal antibody pricing and market trends.
- EvaluatePharma. (2022). Oncology market forecasts.
[1] U.S. Food and Drug Administration. (2020). Prescribing information for Blenrep.
